Clinical Trial Update: Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating a personalized tumor neoantigen mRNA therapy for advanced hepatocellular carcinoma. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Personalized tumor neoantigen mRNA therapy

Snippet

Sponsor: Zhejiang University | Conditions: Advanced Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: RECRUITING